SNPMiner Trials (Home Page)
Report for Mutation C23S
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 5-HT2AR: 5HT2CR Balance in Brain Connectivity in Cocaine Dependence
This project will evaluate the role of the 5-HT2CR:5-HT2AR balance in impulsive action and cue reactivity in cocaine-dependent subjects as compared to non-drug using controls.
NCT03921151 Cocaine Dependence Drug: Mirtazapine 15 MG Oral Tablet Other: Placebo oral capsule MeSH:Cocaine-Related Disorders
Change in Interaction of the serotonin receptor (5-HTR) type-2C Cys23Ser single nucleotide polymorphism (SNP) and a 5-HT2AR antagonist on the functional circuitry underlying impulsive action.. Change in fMRI activation during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose. --- Cys23Ser ---
Change in Interaction of the 5-HT2CR Cys23Ser SNP and a 5-HT2AR antagonist on the functional circuitry underlying cue reactivity. --- Cys23Ser ---
Brain and behavioral responses to the 5-HT2AR blocking medication mirtazapine will be compared between subjects who have high and low functioning of the 5-HT2CR based on presence of a specific, functionally-relevant single nucleotide polymorphism (SNP) of the 5-HT2CR (Cys23Ser). --- Cys23Ser ---
The 5-HT2CR Cys23Ser SNP is thought to decrease the function of the protein and a preliminary observation indicates cocaine-dependent subjects carrying the CC genotype (Ser23 protein variant) display significantly higher cue reactivity. --- Cys23Ser ---
Primary Outcomes
Description: Change in fMRI activation during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose
Measure: Change in Interaction of the serotonin receptor (5-HTR) type-2C Cys23Ser single nucleotide polymorphism (SNP) and a 5-HT2AR antagonist on the functional circuitry underlying impulsive action. Time: Baseline to 1 weekSecondary Outcomes
Description: Change in fMRI activation during Attentional bias task with placebo dose vs Mirtazapine dose
Measure: Change in Interaction of the 5-HT2CR Cys23Ser SNP and a 5-HT2AR antagonist on the functional circuitry underlying cue reactivity Time: Baseline to 1 weekOther Outcomes
Description: Change in Impulsivity as measured by Go/NoGo task with placebo dose vs Mirtazapine dose
Measure: Change in Effective connectivity involved in the 5-HT2AR:5-HT2CR homeostasis impulsive action Time: Baseline to 1 weekDescription: Change in Cue reactivity as measured by Attentional bias task with placebo dose vs Mirtazapine dose
Measure: Change in Effective connectivity involved in the 5-HT2AR:5-HT2CR homeostasis cue reactivity Time: Baseline to 1 weekDescription: Change in fMRI activation with other 5-HT2CR SNPs during Attentional bias task with placebo dose vs Mirtazapine dose
Measure: Change in Explore interactions between other 5-HT2CR SNPs and brain activation during attentional bias task after a 5- HT2AR antagonist Time: Baseline to 1 weekDescription: Change in fMRI activation with other 5-HT2CR SNPs during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose
Measure: Change in Explore interactions between other 5-HT2CR SNPs and brain activation during Go/NoGo (impulsivity) task after a 5- HT2AR antagonist Time: Baseline to 1 week